PE20001608A1 - Uso de (5-aril-1,2,4-tiadiazol)-3-il-urea o (5-aril-1,2,4-tiadiazol)-3-il-tiourea para tratar infecciones virales - Google Patents

Uso de (5-aril-1,2,4-tiadiazol)-3-il-urea o (5-aril-1,2,4-tiadiazol)-3-il-tiourea para tratar infecciones virales

Info

Publication number
PE20001608A1
PE20001608A1 PE2000000286A PE0002862000A PE20001608A1 PE 20001608 A1 PE20001608 A1 PE 20001608A1 PE 2000000286 A PE2000000286 A PE 2000000286A PE 0002862000 A PE0002862000 A PE 0002862000A PE 20001608 A1 PE20001608 A1 PE 20001608A1
Authority
PE
Peru
Prior art keywords
tiadiazol
aril
suspensions
viral infections
thiourea
Prior art date
Application number
PE2000000286A
Other languages
English (en)
Inventor
James Berger Camden
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of PE20001608A1 publication Critical patent/PE20001608A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)

Abstract

SE REFIERE AL USO DE DERIVADO DE (5-ARIL-1,2,4-TIADIAZOL)-3-IL TIOUREA, O DERIVADO DE (5-ARIL-1,2,4-TIADIAZOL)-3-IL UREA DE FORMULA I, DONDE: X ES O, S; R ES H, ALQUILO C1-C3; n ES 1-4; R1 ES H, ALQUILO C1-C7, Cl, Br, F, OXICLORO, ALCOXI O(CH2)y(CH3); y ES 1-6; POR LO MENOS 3 SEMANAS; SIENDO LA DOSIS DE ADMINISTRACION DE 1mg/kg A 1OOOO mmg/kg. TAMBIEN SE REFIERE AL USO DE AZIDOVUDINA (AZT), LAMIVUDINA (TC-3), INHIBIDORES DE PROTEASA. LA COMPOSICION SE PRESENTA EN FORMA SOLIDA E INCLUYE UN PORTADOR TAL COMO LACTOSA SUCROSA, GELATINA, AGAR O SE PRESENTA EN FORMA LIQUIDA TAL COMO SOLUCIONES ACUOSAS, SOLUCIONES ALCOHOLICAS, EMULSIONES, SUSPENSIONES, SUSPENSIONES RECONSTITUIDAS DE PREPPARACIONES Y SUSPENSIONES NO EFERVESCENTES. LA COMPOSICION PUEDE SER UTIL PARA EL TRATAMIENTO DE INFECCIONES VIRALES TAL COMO VIH, HEPATITIS
PE2000000286A 1999-03-31 2000-03-31 Uso de (5-aril-1,2,4-tiadiazol)-3-il-urea o (5-aril-1,2,4-tiadiazol)-3-il-tiourea para tratar infecciones virales PE20001608A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28189599A 1999-03-31 1999-03-31

Publications (1)

Publication Number Publication Date
PE20001608A1 true PE20001608A1 (es) 2001-02-08

Family

ID=23079222

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000000286A PE20001608A1 (es) 1999-03-31 2000-03-31 Uso de (5-aril-1,2,4-tiadiazol)-3-il-urea o (5-aril-1,2,4-tiadiazol)-3-il-tiourea para tratar infecciones virales

Country Status (11)

Country Link
US (2) US6245788B1 (es)
EP (1) EP1165074B1 (es)
JP (1) JP2002540150A (es)
AR (1) AR018985A1 (es)
AT (1) ATE267598T1 (es)
AU (1) AU763275B2 (es)
CA (1) CA2368650C (es)
CO (1) CO5160293A1 (es)
DE (1) DE60011060T2 (es)
PE (1) PE20001608A1 (es)
WO (1) WO2000057869A2 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6245788B1 (en) * 1999-03-31 2001-06-12 The Procter & Gamble Company Viral treatment
EP1214931A1 (en) * 2000-12-15 2002-06-19 Schering Aktiengesellschaft Water-free skin care formulations comprising micronized urea and method of manufacturing the same
TW200600492A (en) * 2004-05-18 2006-01-01 Achillion Pharmaceuticals Inc Substituted aryl acylthioureas and related compounds; inhibitors of viral replication
CA2717119A1 (en) * 2008-03-06 2009-11-12 Mount Sinai School Of Medicine Of New York University Compounds that modulate negative-sense, single-stranded rna virus replication and uses thereof
US9096585B2 (en) 2010-05-28 2015-08-04 Icahn School Of Medicine At Mount Sinai Antiviral compounds and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4353920A (en) 1980-08-25 1982-10-12 Olin Corporation Use of selected 3-trihalomethyl-5-ureido-1,2,4-oxadiazoles and -1,2,4-thiadiazoles as agricultural viricides
JPS57136579A (en) * 1981-01-21 1982-08-23 Mitsui Toatsu Chem Inc Thiazolylurea derivative, its preparation, and pharmaceutical composition containing the same
US4835168A (en) 1985-12-16 1989-05-30 Eli Lilly And Company Thiadiazole antiviral agents
US5256680A (en) 1988-11-29 1993-10-26 Warner-Lambert Company 3,5-di-tertiary-butyl-4-hydroxyphenyl-1,3,4-thiadiazoles, and oxadiazoles and 3,5-di-tertiary-butyl-4-hydroxy-phenyl-1,2,4-thiadazoles, oxadiazoles and triazoles as antiinflammatory agents
IL102548A (en) 1991-08-02 1998-08-16 Medivir Ab Use of painting derivatives in the preparation of drugs for VIH inhibition and treatment of SDIA and new compounds
US5593993A (en) 1991-08-02 1997-01-14 Medivir Ab Method for inhibition of HIV related viruses
JPH06293651A (ja) * 1993-04-07 1994-10-21 Sapporo Breweries Ltd Ｈｉｖ感染予防剤、ａｉｄｓ発症防止剤及びａｉｄｓ治療剤
JPH07149748A (ja) * 1993-09-30 1995-06-13 Souyaku Gijutsu Kenkyusho:Kk チアジアゾール誘導体及びその製造法
JPH08169881A (ja) * 1994-09-22 1996-07-02 Soyaku Gijutsu Kenkyusho:Kk アリールチアジアゾール誘導体及びそれを含有する抗ウイルス剤
JPH08245384A (ja) * 1995-03-13 1996-09-24 Soyaku Gijutsu Kenkyusho:Kk 抗ウイルス剤
US6162791A (en) 1998-03-02 2000-12-19 Apotex Inc. Thiadiazole compounds useful as inhibitors of cysteine activity dependent enzymes
US6258831B1 (en) * 1999-03-31 2001-07-10 The Procter & Gamble Company Viral treatment
US6245788B1 (en) * 1999-03-31 2001-06-12 The Procter & Gamble Company Viral treatment

Also Published As

Publication number Publication date
JP2002540150A (ja) 2002-11-26
CO5160293A1 (es) 2002-05-30
ATE267598T1 (de) 2004-06-15
US20010034358A1 (en) 2001-10-25
WO2000057869A2 (en) 2000-10-05
CA2368650C (en) 2005-09-13
EP1165074B1 (en) 2004-05-26
AR018985A1 (es) 2001-12-12
EP1165074A2 (en) 2002-01-02
DE60011060T2 (de) 2004-10-14
CA2368650A1 (en) 2000-10-05
AU4048800A (en) 2000-10-16
US6245788B1 (en) 2001-06-12
WO2000057869A3 (en) 2001-04-26
US6384064B2 (en) 2002-05-07
AU763275B2 (en) 2003-07-17
DE60011060D1 (de) 2004-07-01

Similar Documents

Publication Publication Date Title
PE20001644A1 (es) Composicion de un derivado de (5-aril-1,2,4-tiadiazol)-3-il tiourea o un derivado de (5-aril-1,2,4-tiadiazol)-3-il urea para tratar infecciones virales
RU2004110719A (ru) Зздабиторы протеаз, расщепляющих за пролином
PE20060837A1 (es) COMPUESTOS DE 3H-OXAZOLO Y 3H-TIAZOLO[4,5-d]PIRIMIDIN-2-ONA 3,5-DISUSTITUIDA Y 3,5,7-TRISUSTITUIDA Y PROFARMACOS DE LOS MISMOS
BRPI0412761A (pt) inibidores de serino proteases, particularmente a protease ns3-ns4a do vhc
KR960034164A (ko) 스틸벤 유도체 및 이를 함유하는 약제학적 조성물
PE10399A1 (es) Derivados de aminoacidos
EA200600225A1 (ru) Производные пиперазина для лечения вич инфекций
PE20130209A1 (es) Derivados de uracilo o timina para tratar la hepatitis c
BRPI0414176A (pt) inibidores de serina proteases, em particular hcv ns3-ns4a protease
PE20080197A1 (es) Combinaciones que involucran el (los) inhibidor (es) de la proteasa del hcv, y metodos de tratamiento relacionado al (los) mismos(s)
HUP0400856A2 (hu) Gombaellenes készítmény
DE50310721D1 (de) Tubulysine, herstellungsverfahren und tubulysin-mittel
NZ609146A (en) Modified 4’-nucleosides as antiviral agents
SE0102438D0 (sv) New compounds
PE20000048A1 (es) Prodrogas de inhibidores de aspartil proteasa
KR930702371A (ko) 뉴클레오시드 유도체
EA199800752A1 (ru) Пентафторбензолсульфонамиды и их аналоги
DE60214179D1 (de) IMIDAZOi1,2-AöPYRIDIN-DERIVATE ZUR PROPHYLAXE UND BEHANDLUNG VON HERPES-INFEKTIONEN
KR920018028A (ko) 콜레스테롤 생합성 억제제로서의 신규 아자데칼린 아미드 및 티오아미드
MA28286A1 (fr) Dérivés de 1-N-phenyl-amino-1H-imidazole et compositions pharmaceutiques les contenant
PE20001608A1 (es) Uso de (5-aril-1,2,4-tiadiazol)-3-il-urea o (5-aril-1,2,4-tiadiazol)-3-il-tiourea para tratar infecciones virales
BR0214937A (pt) Processo de preparação de derivados de equinocandina
UA84020C2 (ru) Ингибитор проникновения вируса вил
ATE124050T1 (de) Chirale 2-(phosphonomethoxy)propyl-guanine als antivirale agentien.
EA200100956A1 (ru) Фармацевтические композиции на основе тизоксанида и нитазоксанида

Legal Events

Date Code Title Description
FC Refusal